# EDGAR Filing Document

**Accession Number:** 0001460602
**File Stem:** 0001493152-26-003501
**Filing Date:** 2026-1
**Character Count:** 31347
**Document Hash:** 3eed624866be129df68db0dfd337d049
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-003501.hdr.sgml**: 20260126

**ACCESSION NUMBER**: 0001493152-26-003501

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260114

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260126

**DATE AS OF CHANGE**: 20260126

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Orgenesis Inc.
- **CENTRAL INDEX KEY:** 0001460602
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 980583166
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38416
- **FILM NUMBER:** 26558357

**BUSINESS ADDRESS:**
- **STREET 1:** 20271 GOLDENROD LANE
- **CITY:** GERMANTOWN
- **STATE:** MD
- **ZIP:** 20876
- **BUSINESS PHONE:** (480) 659-6404

**MAIL ADDRESS:**
- **STREET 1:** 20271 GOLDENROD LANE
- **CITY:** GERMANTOWN
- **STATE:** MD
- **ZIP:** 20876

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Orgenesis, Inc.
- **DATE OF NAME CHANGE:** 20110902

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Business Outsourcing Service, Inc.
- **DATE OF NAME CHANGE:** 20090401

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **<u>January 14th, 2026</u>**

**<u>ORGENESIS INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-38416** | **98-0583166** |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation | File Number) | Identification No.) |

---

**<u>20271 Goldenrod Lane, Germantown, MD 20876</u>**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **<u>(480) 659-6404</u>**

**<u>Not Applicable</u>**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(g) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, par value $0.0001 per share** | **ORGS** | **OTC Expert Market\*** |

---

\* On October 17, 2024, the Nasdaq Stock Market ("Nasdaq") notified Orgenesis Inc. (the "Company") that it planned to file a notification of removal from listing (Form 25) with the Securities and Exchange Commission (the "SEC") to delist the Company's common stock from Nasdaq upon the completion of all applicable procedures. Nasdaq filed the Form 25 on May 8, 2025. The deregistration of the Company's common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), occurred 90 days following the filing of the Form 25. Upon deregistration of the Company's common stock under Section 12(b) of the Exchange Act, the Company's common stock remained registered under Section 12(g) of the Exchange Act. The Company's common stock began trading on the OTCQX operated by the OTC Markets Group, Inc. ("OTC Markets") beginning on October 21, 2024. On June 3, 2025, OTC Markets moved the Company's common stock from OTCQX to the Pink Limited tier. On July 29, 2025, OTC Markets moved the Company's common stock from Pink Limited to the OTC Expert Market tier.

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b -2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement.**

As previously disclosed in a Current Report on Form 8-K filed on September 16, 2025, Orgenesis Inc. (the "Company") entered into that certain Convertible Loan Agreement, dated September 10, 2025, by and among Theracell Laboratories IKE, the Company and Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P (the "Lender") with respect to a $1,000,000 convertible loan, a $10,000,000 credit facility and the issuance of warrants related thereto (the "Convertible Loan Agreement"). Pursuant to the Convertible Loan Agreement, the Company is required to issue to Lender a warrant to purchase 15% of the fully diluted share capital of either the Company or Theracell, at the Lender's discretion, for an aggregate exercise price of $250,000 and exercisable for three years from issuance with respect to each cumulative drawdown of $1,000,000 under the loan and credit facility referenced above. With respect to the first $1,000,000 drawdown, on January 9th, 2026, the Company issued to Lender a warrant (the "Alpha Warrant") exercisable for 3,289,490 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), with a three year expiration and an aggregate exercise price equal to $250,000.

The foregoing summary of the form of Alpha Warrant described herein does not purport to be complete and is subject to, and qualified in its entirety by, the full text of such document attached as Exhibit 4.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

**Item 3.02. Unregistered Sales of Equity Securities.**

The Alpha Warrant and the shares of Common Stock issuable upon exercise of such Warrant have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), and shall be exempt from registration under Section 4(a)(2) of the Securities Act as a transaction not involving a public offering. The information contained in Item 1.01 above is hereby incorporated by reference into this Item 3.02.

**Item 9.01. Financial Statements and Exhibits.**

The exhibit listed in the following Exhibit Index is filed as part of this Current Report on Form 8-K.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 4.1 | [Form of Alpha Warrant, dated as of January 9th, 2026](ex4-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ORGENESIS INC.** | **ORGENESIS INC.** |
| Date: January 26th, 2026 | By: | */s/ Vered Caplan* |
|  |  | Vered Caplan |
|  |  | Chief Executive Officer |

---

## Exhibit 4.1

**Exhibit 4.1**

**THESE WARRANTS ARE NOT TRANSFERABLE**

**THESE SECURITIES WERE ISSUED IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE 1933 ACT) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"). ACCORDINGLY, NONE OF THE SECURITIES TO WHICH THIS CERTIFICATE RELATES HAVE BEEN REGISTERED UNDER THE 1933 ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, NONE MAY BE OFFERED OR SOLD IN THE UNITED STATES OR, DIRECTLY OR INDIRECTLY, TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN ACCORDANCE WITH THE 1933 ACT.**

**ORGENESIS INC.**

(A Nevada Corporation)

**NON-TRANSFERABLE**

**WARRANT CERTIFICATE**

**CERTIFICATE NO. W - 507**

---

| | | | |
|:---|:---|:---|:---|
| **NUMBER OF WARRANTS:** | **3,289,490** | **RIGHT TO PURCHASE** | **3,289,490 SHARES** |

---

THESE NON-TRANSFERABLE WARRANTS WILL EXPIRE AND BECOME NULL AND VOID

AT 5:00 P.M. (PACIFIC TIME) ON THE EXPIRY DATE (AS DEFINED IN THE TERMS AND

CONDITIONS ATTACHED TO THIS WARRANT CERTIFICATE.

NON-TRANSFERABLE SHARE PURCHASE WARRANTS

TO PURCHASE SHARES OF COMMON STOCK OF ORGENESIS INC.

**THE WARRANTS REPRESENTED BY THIS CERTIFICATE**

This is to certify that, for value received, Alpha Prosperity Fund SPL (the **"Holder"**) has the right to purchase, upon and subject to the terms and conditions attached hereto as Appendix "A" (the **"Terms and Conditions"**) from January 9th , 2026 to 5:00 p.m. (Eastern Time) on the Expiry Date (as defined in the attached Terms and Conditions), the number of fully paid and non-assessable shares of common stock (the **"Shares"**) of Orgenesis Inc. (the **"Company"**) set out above, by surrendering to the Company, at its offices at 20271 Goldenrod Lane, Germantown, MD 20876, this Warrant Certificate with a Subscription in the form attached hereto as Appendix "B", duly completed and executed, and cash, bank draft, certified cheque or money order in lawful money of the United States of America, payable to the order of the Company in an amount equal to the purchase price per Share multiplied by the number of Shares being purchased (the "**Aggregate Purchase Price**"). Subject to adjustment thereof in the events and in the manner set forth in the Terms and Conditions, the purchase price per Share on the exercise of each Non-Transferable Share Purchase Warrant (**"Warrant"**) evidenced hereby shall be **US $0.076.**

These Warrants are issued subject to the Terms and Conditions, and the Holder may exercise the right to purchase Shares only in accordance with the Terms and Conditions.

Nothing contained herein or in the Terms and Conditions will confer any right upon the Holder or any other person to subscribe for or purchase any Shares at any time subsequent to the Expiry Date and from and after such time, these Warrants and all rights hereunder will be void and of no value.

IN WITNESS WHEREOF the Company has caused this Warrant Certificate to be executed.

DATED at Germantown, in the State of Maryland, on this 9th day of January 2026.

---

| | |
|:---|:---|
| **ORGENESIS INC.** | **ORGENESIS INC.** |
| Per: | |
| Name: | Vered Caplan |
| Title: | Chief Financial Officer |

---

PLEASE NOTE THAT ALL SHARE CERTIFICATES ISSUED UPON EXERCISE HEREOF MUST BE LEGENDED AS FOLLOWS:

"THESE SECURITIES WERE ISSUED IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE 1933 ACT) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"). ACCORDINGLY, NONE OF THE SECURITIES TO WHICH THIS CERTIFICATE RELATES HAVE BEEN REGISTERED UNDER THE 1933 ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, NONE MAY BE OFFERED OR SOLD IN THE UNITED STATES OR, DIRECTLY OR INDIRECTLY, TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN ACCORDANCE WITH THE 1933 ACT."

APPENDIX "A"

TERMS AND CONDITIONS dated as of January 9th , 2026 (the "Terms and Conditions"), attached to the Non-Transferable Share Purchase Warrants issued by Orgenesis Inc.

**1.**  **<u>Definitions</u>** 

In these Terms and Conditions, unless there is something in the subject matter or context inconsistent therewith:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) "Business
 Days" means any day other than a Saturday, Sunday, or a day on which banking institutions in the State of Nevada are authorized
 or obligated by law or executive order to close.

(b) "Company"
 means Orgenesis Inc., a Nevada corporation. If a successor corporation will have become such as a result of consolidation, amalgamation
 or merger with or into any other corporation or corporations, or as a result of the conveyance or transfer of all or substantially
 all of the properties and estates of the Company as an entirety to any other corporation and thereafter "Company" will
 mean such successor corporation;

(c) "Company's
 Auditors" means an independent firm of accountants duly appointed as auditors of the Company;

(d) "Exercise
 Price" means US $0.076 per Share, subject to adjustment as provided in the Terms and Conditions;

(e) "Expiry
 Date" means January 9th , 2029;

(f) "herein",
 "hereby" and similar expressions refer to these Terms and Conditions as the same may be amended or modified from time
 to time; and the expression "Section" followed by a number refer to the specified Section of these Terms and Conditions;

(g) "person"
 means an individual, corporation, partnership, trustee or any unincorporated organization and words importing persons have a similar
 meaning;

(h) "Holder"
 or "Holders" means the holder of the Warrants and its heirs, executors, administrators, successors, legal representatives
 and assigns;

(i) "Shares"
 means the shares of common stock in the capital of the Company as constituted at the date hereof and any shares resulting from any
 subdivision or consolidation of such shares, issued upon exercise of the Warrants;

(j) "Warrants"
 means the Non-Transferable Share Purchase Warrants of the Company issued and presently authorized and for the time being outstanding;
 and

(k) "1933
 Act" means the United States Securities Act of 1933.

**2.**  **<u>Interpretation</u>** 

The division of these Terms and Conditions into sections and the insertion of headings are for convenience of reference only and shall not affect the construction or interpretation thereof. Words importing the singular number include the plural and vice versa and words importing the masculine gender include the feminine and neuter genders.

**3.**  **<u>Applicable Law</u>** 

The rights and restrictions attached to the Warrants shall be construed in accordance with the laws of the State of Nevada.

**4.**  **<u>Additional Issuances of Securities</u>** 

The Company may at any time and from time to time do further equity or debt financing and may issue additional shares, warrants, convertible securities, stock options or similar rights to purchase shares of its capital stock.

**5.**  **<u>Replacement of Lost Warrants</u>** 

5.1 In
 case this Warrant Certificate shall become mutilated, lost, destroyed or stolen, the Company in its discretion may issue and deliver
 a new Warrant Certificate of like date and tenure as the one mutilated, lost, destroyed or stolen, in exchange for and in place of
 and upon cancellation of such mutilated Warrant Certificate, or in lieu of, and in substitution for such lost, destroyed or stolen
 Warrant Certificate and the substituted Warrant Certificate shall be entitled to all benefits hereunder and rank equally in accordance
 with its terms with all other Warrants issued or to be issued by the Company.

5.2 The
 applicant for the issue of a new Warrant Certificate pursuant hereto shall bear the cost of the issue thereof and in case of loss,
 destruction or theft shall furnish to the Company evidence of ownership and of loss, destruction or theft of the Warrant Certificate
 so lost, destroyed or stolen as shall be satisfactory to the Company and its transfer agent in accordance with its usual policies
 and procedures and such applicant may also be required to furnish indemnity in the amount and form satisfactory to the Company and
 its transfer agent in accordance with its usual policies and procedures, and shall pay the reasonable charges of the Company in connection
 therewith.

**6.**  **<u>Warrant Holder Not a Shareholder</u>** 

The holding of a Warrant Certificate will not constitute the Holder as a shareholder of the Company, nor entitle the Holder to any right or interest in respect thereof except as is expressly provided in the Warrant Certificate or these Terms and Conditions.

**7.**  **<u>Warrants Not Transferable</u>** 

The Warrants and all rights attached thereto are transferable at the discretion of warrant holder provided that such transfer does not contravene any law.

**8.**  **<u>Notice to Holders</u>** 

Any notice required or permitted to be given to the Holder will be in writing and may be given by prepaid registered post, electronic facsimile transmission or other means of electronic communication capable of producing a printed copy to the address of the Holder appearing on the Warrant Certificate or to such other address as any Holder may specify by notice in writing to the Company, and any such notice will be deemed to have been given and received by the Holder to whom it was addressed if mailed, on the third day following the mailing thereof, if by facsimile or other electronic communication, on successful transmission, or, if delivered, on delivery; but if at the time of mailing or between the time of mailing and the third Business Day thereafter there is a strike, lockout, or other labour disturbance affecting postal service, then the notice will not be effectively given until actually delivered.

**9.**  **<u>Notice to the Company</u>** 

Any notice required or permitted to be given to the Company will be in writing and may be given by prepaid registered post, electronic facsimile transmission or other means of electronic communication capable of producing a printed copy to the address of the Company set forth below or such other address as the Company may specify by notice in writing to the Holder, and any such notice will be deemed to have been given and received by the Company to whom it was addressed if mailed, on the third day following the mailing thereof, if by facsimile or other electronic communication, on successful transmission, or, if delivered, on delivery; but if at the time or mailing or between the time of mailing and the third Business Day thereafter there is a strike, lockout, or other labour disturbance affecting postal service, then the notice will not be effectively given until actually delivered:

Orgenesis Inc.

20271 Goldenrod Lane

Germantown, MD 20876

Attention: Vered Caplan, CEO

**10.**  **<u>Method of Exercise of Warrants</u>** 

The right to purchase Shares conferred by the Warrants may be exercised by the Holder of such Warrant by surrendering it to the Company, with a duly completed and executed subscription in the form attached as Appendix "B" and cash, bank draft, certified cheque or money order payable to or to the order of the Company for the Aggregate Purchase Price subscribed for in lawful money of the United States of America.

**11.**  **<u>Effect of Exercise of Warrants</u>** 

11.1 Upon
 surrender and payment as aforesaid, the Shares so subscribed for shall be deemed to have been issued and such Holder shall be deemed
 to have become the holder (or holders) of record of such Shares on the date of such surrender and payment and such Shares shall be
 issued at the Exercise Price in effect on the date of such surrender and payment.

11.2 Within
 ten Business Days after surrender and payment as aforesaid, the Company shall forthwith cause to be delivered to the person or persons
 in whose name or names the Shares so subscribed for are to be issued as specified in such subscription or mailed to him or them at
 his or their respective addresses specified in such subscription, a certificate or certificates for the appropriate number of Shares
 not exceeding those which the Holder is entitled to purchase pursuant to the Warrant surrendered.

**12.**  **<u>Subscription for Less than Entitlement</u>** 

The Holder of any Warrant may subscribe for and purchase a number of Shares less than the number which he is entitled to purchase pursuant to the surrendered Warrant. In the event of any purchase of a number of Shares less than the number which can be purchased pursuant to a Warrant, the Holder, upon exercise thereof, shall be entitled to receive a new Warrant Certificate in respect of the balance of the Shares which he was entitled to purchase pursuant to the surrendered Warrant Certificate and which were not then purchased.

**13.**  **<u>Warrants for Fractions of Shares</u>** 

To the extent that the Holder of any Warrant is entitled to receive on the exercise or partial exercise thereof a fraction of a Share, such right may be exercised in respect of such fraction only in combination with another Warrant or other Warrants which in the aggregate entitle the Holder to receive a whole number of such Shares.

**14.**  **<u>Expiration of Warrants</u>** 

After the expiration of the period within which a Warrant is exercisable, all rights thereunder shall wholly cease and terminate and such Warrants shall be void and of no further force and effect.

**15.**  **<u>Adjustment of Exercise Price</u>** 

The Exercise Price and the number of Shares deliverable upon the exercise of the Warrants shall be subject to adjustment in the event and in the manner following:

15.1 If
 and whenever the Shares at any time outstanding shall be subdivided into a greater or consolidated into a lesser number of Shares,
 the Exercise Price shall be decreased or increased proportionately, as the case may be, and upon any such subdivision or consolidation,
 the number of Shares deliverable upon the exercise of the Warrants shall be increased or decreased proportionately, as the case may
 be.

15.2 In
 case of any capital reorganization or of any reclassification of the capital of the Company or in case of the consolidation, merger
 or amalgamation of the Company with or into any other company or of the sale of the assets of the Company as or substantially as
 an entirety or of any other company, each Warrant shall, after such capital reorganization, reclassification of capital, consolidation,
 merger, amalgamation or sale, confer the right to purchase that number of shares or other securities or property of the Company or
 of the company resulting from such capital reorganization, reclassification, consolidation, merger, amalgamation or to which such
 sale shall be made, as the case may be, to which the Holder of the shares deliverable at the time of such capital reorganization,
 reclassification of capital, consolidation, merger, amalgamation or sale had the Warrants been exercised, would have been entitled
 on such capital reorganization, reclassification, consolidation, merger, amalgamation or sale and in any such case, if necessary,
 appropriate adjustments shall be made in the application of the provisions set forth in Sections 12 to 19 hereof with respect to
 the rights and interest thereafter of the Holders of the Warrants to the end that the provisions set forth in Sections 12 to 19 hereof
 shall thereafter correspondingly be made applicable as nearly as may reasonable be expected in relation to any shares or other securities
 or property thereafter deliverable on the exercise of the Warrants. The subdivision or consolidation of the Shares at any time outstanding
 into a greater or lesser number of Shares (whether with or without par value) shall not be deemed to be a capital reorganization
 or a reclassification of the capital of the Company for the purposes of this Section ‎15.

15.3 This
 section intentionally left blank.

15.4 The
 adjustments provided for in this Section ‎15 pursuant to any Warrants are cumulative and will become effective immediately after
 the record date for, or, if no record date is fixed, the effective date, of the event which results in such adjustments.

**16.**  **<u>Determination of Adjustments</u>** 

If any questions shall at any time arise with respect to the Exercise Price or any adjustments provided for in this Warrant, such questions shall be conclusively determined by the Company's Auditors, from time to time, or, if they decline to so act, any other firm of chartered accountants that the Company may designate and who shall have access to all appropriate records and such determination shall be binding upon the Company and the Holders.

**17.**  **<u>Covenants of the Company</u>** 

The Company will reserve and there will remain unissued out of its authorized capital a sufficient number of Shares to satisfy the rights of purchase provided for in the Warrants should the Holders of all the Warrants from time to time outstanding determine to exercise such rights in respect of all Shares which they are or may be entitled to purchase pursuant thereto.

**18.**  **<u>Immunity of Shareholders, etc.</u>** 

The Holder hereby waives and releases any right, cause of action or remedy now or hereafter existing in any jurisdiction against any past, present or future incorporator, shareholder, director or officer (as such) of the Company for the issue of Shares pursuant to any Warrant or on any covenant, agreement, representation or warranty by the Company herein contained.

**19.**  **<u>Modification of Terms and Conditions for Certain Purposes</u>** 

From time to time the Company may, subject to the provisions of these presents, and it shall, when so directed by these presents, modify the terms, and conditions hereof, for any one or more of any of the following purposes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) making
 such provisions not inconsistent herewith as may be necessary or desirable with respect to matters or questions arising hereunder
 or for the purpose of obtaining a listing or quotation of the Warrants on any stock exchange or quotation system;

(b) adding
 to or altering the provisions hereof in respect of the registration and transfer of Warrants making provisions for the exchange of
 Warrants of different denominations; and making any modification in the form of the Warrants which does not affect the substance
 thereof;

(c) for
 any other purpose not inconsistent with the terms hereof, including the correction or recertification of any ambiguities, defective
 provisions, errors or omissions herein; and

(d) to
 evidence any successions of any corporation and the assumption of any successor of the covenants of the Company herein and in the
 Warrants contained as provided herein.

**20.**  **<u>United States Restrictions</u>** 

These Warrants and the Shares issuable upon the exercise of these Warrants have not been and will not be registered under the 1933 Act as amended or any state securities laws. These Warrants may not be exercised in the United States (as defined in Regulation S under the 1933 Act) unless these Warrants and the Shares issuable upon exercise hereof have been registered under the 1933 Act, and any applicable state securities laws or unless an exemption from such registration is available.

DATED as of the date first above written in these Terms and Conditions.

---

| | |
|:---|:---|
| **ORGENESIS INC.** | **ORGENESIS INC.** |
| By: |  |
| Name: | Vered Caplan |
| Title: | Chief Executive Officer |

---

APPENDIX "B"

**<u>SUBSCRIPTION FORM</u>**

(ONE NON-TRANSFERABLE SHARE PURCHASE WARRANT IS

REQUIRED TO SUBSCRIBE FOR EACH SHARE OF COMMON STOCK)

---

| | |
|:---|:---|
| **TO:** | ORGENESIS INC. |
|  | 20271 Goldenrod Lane |
|  | Germantown, MD 20876 |

---

The undersigned, bearer of the attached Non-Transferable Share Purchase Warrants, hereby subscribes for _____________ of shares of common stock (the "**Shares**") of Orgenesis Inc. (the **"Company"**) referred to in the Warrants according to the conditions thereof and herewith makes payment of the purchase price in full for the said number of shares at the price of U.S. $0.076 per Share if exercised on or before 5:00 p.m. (Eastern Time) on the Expiry Date (as that term is defined in the Terms and Conditions attached to the Non-Transferable Share Purchase Warrant). Cash, a certified cheque, bank draft or money order is enclosed herewith for such amount.

The undersigned hereby directs that the shares hereby subscribed for be issued and delivered as follows:

---

| | | |
|:---|:---|:---|
| **Name(s) in Full** | **Address(es)** | **Number of Shares** |

---

(Please print full names in which share certificates are to be issued. The Shares must be issued in the name of the Holder.)

DATED this ______ day of ___________________ , 20___ . (the "**Exercise Date**")

---

| | |
|:---|:---|
| Witness | Signature |
| Please print your name and address in full |  |
| | Address |

---

**<u>TERMS AND CONDITIONS</u>**

The Warrants are issued subject to the Terms and Conditions, which are attached to the Warrant Certificate delivered to the Holder.

**<u>REPRESENTATIONS AND WARRANTIES</u>**

The undersigned represents and warrants that the undersigned is not a "U.S. person", as such term is defined in Regulation S as promulgated under the United States Securities Act of 1933, as at the Exercise Date. The undersigned represents and warrants that the representations and warranties in the subscription agreement between the undersigned and the Company dated the Holder are true and correct as of the date of the Exercise Date.

**<u>LEGENDS</u>**

The certificates representing the Shares acquired on the exercise of the Warrants will bear a legend in substantially the following form:

"THESE SECURITIES WERE ISSUED IN AN OFFSHORE TRANSACTION TO A PERSON WHO IS NOT A U.S. PERSON (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"). ACCORDINGLY, NONE OF THE SECURITIES TO WHICH THIS CERTIFICATE RELATES HAVE BEEN REGISTERED UNDER THE 1933 ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, NONE MAY BE OFFERED OR SOLD IN THE UNITED STATES (AS DEFINED HEREIN) OR, DIRECTLY OR INDIRECTLY, TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN ACCORDANCE WITH THE 1933 ACT. "UNITED STATES" AND "U.S. PERSON" ARE AS DEFINED BY REGULATION S UNDER THE 1933 ACT."